This research study is a Phase II clinical trial. Phase II clinical trials test the
effectiveness of a therapy to learn whether the therapy works in treating a specific cancer.
"Investigational" means that the therapy is still being studied and that research doctors are
trying to find out more about it-such as the safest dose to use, the side effects it may
cause, and if therapy is effective for treating different types of cancer. Proton beam
radiation therapy is an FDA (U.S. Food and Drug Administration) approved radiation delivery
system.
Proton beam radiation therapy is known to spare surrounding normal tissues from radiation as
it delivers less radiation beyond the area of the target tissues. This may reduce side
effects that patients would normally experience with standard (photon) radiation therapy,
which tends to include more normal tissue along with tumor target tissue.
Researchers in the laboratory have discovered that there are pathways inside the cells that
can lead to growth and survival of the tumor. The chemotherapy drugs FOLFIRINOX and
capecitabine are targeted towards blocking the pathways that allow cancer cells to divide,
and may result in the tumor shrinking in size.
In this research study, the investigators are looking to determine if proton beam radiation
in combination with FOLFIRINOX and capecitabine is effective in controlling the growth of
your cancer.